瑞波西汀与帕罗西汀治疗抑郁症对照研究

目的探讨瑞波西汀与帕罗西汀治疗抑郁症的临床疗效和安全性。方法将60例抑郁症患者随机分为两组各30例,研究组口服瑞波西汀,对照组口服帕罗西汀,观察8周。于治疗前及治疗1、2、4、6、8周末用汉密顿抑郁量表评定临床疗效,副反应量表评定不良反应。结果治疗8周末研究组总有效率86.67%,对照组83.33%。两组差异无显著性(P0.05)。两组治疗各时段汉密顿抑郁量表总分均较治疗前有显著下降,差异有统计学意义(P0.05,P0.01)。治疗1周、2周研究组较对照组下降显著(P0.05),其他时段无统计学意义(P0.05)。两组不良反应均较轻微,多出现在治疗初期。研究组发生率为23.33%,对照组发生率为26.67%,差异无统计学意义(P0.05)。结论瑞波西汀与帕罗西汀治疗抑郁症疗效显著,安全性高,依从性好,并且瑞波西汀起效较帕罗西汀迅速。

Reboxetine and Paroxetine for Depression: A Control Study

Objective To explore the clinical efficacy and safety of reboxetine and paroxetine in the treatment of depression. Meth- ods Sixty cases were randomly divided into research group（n=30） that was given orally reboxetine and control group （n=30） that was given paroxetine for 8 weeks. The curative efficacy was assessed with the Hamilton Depression Scale（HAMD） and the adverse reactions with the Treatment Emergent Symptom Scale （TESS） before treatment and at the ends of 1, 2, 4 ,6 and 8 weeks. Results After 8 week treatment, the total effective rate of the research group was 86.67% and that of the control group was 83.33%, with no significant difference （P~O.05）. The HAMD total scores of both groups were significantly lowered at＇every time points after treatment compared with pre-treatment, with a significant difference （P〈0.05 or P〈0.01）. The scores of the research group were significantly lowered at Weeks land 2 than those of the control group （P〈0.05）, with no significant difference at other time points（P〉0.05）.Adverse reactions of both groups were mild. Conclusion Both reboxetine and paroxetine have evident effects, higher safety and better compliance in the treatment of depression, but the former shows a faster effect.